cardiac transplantation; heart transplant
Jump to navigation
Jump to search
Indications
- refractory cardiogenic shock
- dependence on intravenous inotropic support
- VO2max < 10-14 mL/kg/min (severely limited functional capacity)*
- severe ischemia (limiting functional capacity) despite optimal medical therapy not amenable to reperfusion (CABG, PCI)
- recurrent significant ventricular arrhythmia refractory to therapy[2]
- insufficient indication alone
- low LV ejection fraction
- history of NYHA HF class 3 or 4[2]
- other criteria considered (may be center-dependent)
- < 60 years of age; < 70 years of age[13]
- strong psychosocial support system
- free of extra-cardiac organ dysfunction that would complicate recovery
- exhausted all other therapeutic options
* despite optimal medical therapy
Contraindications
(may be center-dependent)
- diabetes with end-organ damage, nephropathy, retinopathy
- major chronic disabling illness
- severe pulmonary hypertension
- severe peripheral vascular disease
- active infection
- significant chronic & likely functional impairment of other vital organs (renal failure, cirrhosis, COPD ...)
- active substance abuse (including smoking)
- obesity
- current mental or psychosocial instability
- active or recent malignancy[2]
Clinical manifestations
- due to absence of normal vagal tone, resting heart rate is typically 90-110/min[2]
Laboratory
- cardiac transplantation 20 mRNA expression analysis (CPT)
- routine within 1st 6 months to assess asymptomatic rejection[2]
- endomyocardial biopsy is alternative[2]
Complications
- acute cellular rejection
- most recipients experience 2-3 rejections during the 1st 6 months
- rejection after 12-24 months is uncommon unless immunosuppression has been decreased
- patients > 55 years of age experience less rejection
- manifests as left ventricula dysfinction resulting in acute heart failure
- atrial flutter & atrial fibrillation common
- rejection severity is graded by histopathologic changes on endomyocardial biopsy
- acute humoral rejection
- interstitial edema with deposition of immunoglobulin & complement
- rarely observed > 6 weeks after transplantation
- presents with severe left ventricular dysfunction
- infection secondary to immunosuppression
- effects of immunosuppression are maximal 6-12 weeks after transplantaion
- most frequent cause of death in the 1st year following transplantation
- bacterial infections are common in the 1st month
- viral & opportunistic infections occur later
- pneumonitis is the most common early & late infection
- 30% of patients experience at least 1 major infection after transplantation
- cytomegalovirus within the 1st year[2]
- most important infectious cause of morbidity
- generally occurs 6-12 weeks following transplantation
- infection from donor organ (hepatitis C)[14]
- HCV seropositive donor confers survival disadvantage[3]
- cardiac allograft vasculopathy
- post-transplant coronary artery disease (CAD) is the primary cause of death >1 year after transplant
- occurs in > 32-50% of patients within 5 years[2][7]
- most common cause of heart failure
- uncommon to present as chest pain (transplanted heart lacks innervation)
- represents diffuse intimal hyperplasia rather than focal coronary artery stenosis
- revascularization generally not beneficial
- cyclosporine-induced hypertension
- obesity & hyperlipidemia
- increased risk of malignancy
- skin cancer
- B-cell lymphoma associated with Epstein-Barr virus- induced B-cell proliferation
- lung cancer[4]
- substantial radiation exposure (children)[8]
- increased risk of cancer later in life, especially
Management
- transplant rejection
- endomyocardial biopsy is used to assess rejection[2]
- absence of or non-specific signs/symptoms of mild to moderate rejection
- weekly for 1st pre-operative month
- biweekly for next 2 months
- then reduce to 2-4 times/year
- clinical manifestations of severe rejection
- immunosuppressive therapy:
- cyclosporine
- glucocorticoids
- azathioprine
- severe rejection
- plasmapheresis for acute humoral rejection
- endomyocardial biopsy is used to assess rejection[2]
- treatment of cyclosporine-induced hypertension
- Ca+2 channel blockers are 1st line agents
- addition of 2nd agent often required
- treatment of hyperlipidemia
- assessment of coronary artery disease (CAD)
- angina pectoris does not occur because of lack of innervation
- CAD may present as dyspnea on exertion[2]
- routine ECG to assess silent ischemia/infarction
- thallium-201/MIBI scintigraphy generally unreliable
- dobutamine echocardiography generally unreliable
- coronary angiography is generally method of choice
- intracoronary vascular ultrasonography may be better than angiography
- retransplantation is only treatment for multivessel disease
- angina pectoris does not occur because of lack of innervation
- lymphoma often regresses following reduction in immunosuppression
- survival:
- 90% at 1 year
- 65-70% at 5 years
More general terms
More specific terms
Additional terms
References
- ↑ Manual of Medical Therapeutics, 28th ed, Ewald & McKenzie (eds), Little, Brown & Co, Boston, 1995, pg 125
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 Medical Knowledge Self Assessment Program (MKSAP) 11, 15, 16, 17, 18, 19 American College of Physicians, Philadelphia 1998, 2009, 2012, 2015, 2018, 2022.
- ↑ 3.0 3.1 Gasink LB et al, Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA 2006, 296:1843 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17047214
Qamar AA and Rubin RH Poorer outcomes for recipients of heart allografts from HCV-positive donors: Opening the silos. JAMA 2006, 296:1900 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17047220 - ↑ 4.0 4.1 Engels EA et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011 Nov 2; 306:1891. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22045767
- ↑ Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation. 2005 Jan 18;111(2):230-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15657387
- ↑ Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010 Jul 13;122(2):173-83 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20625142
- ↑ 7.0 7.1 Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation. 2008 Apr 22;117(16):2131-41 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18427143
- ↑ 8.0 8.1 Johnson JN et al Cumulative Radiation Exposure and Cancer Risk Estimation in Children with Heart Disease. Circulation. June 9, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24914037 <Internet> http://circ.ahajournals.org/content/early/2014/05/08/CIRCULATIONAHA.113.005425.abstract
Andreassi MG and Picano E Reduction of Radiation to Children: Our Responsibility to Change. Circulation. June 9, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24914036 <Internet> http://circ.ahajournals.org/content/early/2014/05/08/CIRCULATIONAHA.114.010699.abstract - ↑ Garbade J, Barten MJ, Bittner HB, Mohr FW. Heart transplantation and left ventricular assist device therapy: two comparable options in end-stage heart failure? Clin Cardiol. 2013 Jul;36(7):378-82 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23595910
- ↑ Toyoda Y, Guy TS, Kashem A. Present status and future perspectives of heart transplantation. Circ J. 2013;77(5):1097-110. Epub 2013 Apr 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23614963
- ↑ Mehra MR, Kobashigawa J, Starling R et al Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant J Heart Lung Transplant. 2006 Sep;25(9):1024-42. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16962464
- ↑ Birati EY, Rame JE. Post-heart transplant complications. Crit Care Clin. 2014 Jul;30(3):629-37. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24996612
- ↑ 13.0 13.1 Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019
- ↑ 14.0 14.1 Montgomery RA Perspective. Getting Comfortable with Risk. N Engl J Med 2019; 381:1606-1607. Oct 24. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31644844 https://www.nejm.org/doi/full/10.1056/NEJMp1906872
- ↑ National Heart, Lung, and Blood Institute (NHLBI) Heart Transplant https://www.nhlbi.nih.gov/health-topics/heart-transplant